PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy

BACKGROUND: Programmed cell death protein 1 (PD-1) antibody has been approved for a variety of tumors, but its effective rate is unsatisfactory. New evidence suggests that mast cells are an important component of the tumor microenvironment and are associated with resistance to immunotherapy, but the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jun, Peng, Gang, Zhu, Kuikui, Jie, Xiaohua, Xu, Yingzhuo, Rao, Xinrui, Xu, Yunhong, Chen, Yunshang, Xing, Biyuan, Wu, Gang, Shi, Liangliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947072/
https://www.ncbi.nlm.nih.gov/pubmed/36018370
http://dx.doi.org/10.1007/s00262-022-03282-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947072/
https://www.ncbi.nlm.nih.gov/pubmed/36018370
http://dx.doi.org/10.1007/s00262-022-03282-6

Ejemplares similares